The Best of 2012: Infinity Pharmaceuticals
It's the end of 2012, and that means it's time to take a look back at the year in retrospect. We'll be reading through the naughty and nice lists (we've already checked them twice), counting down the 25 best-performing stocks and the 25 worst-performing stocks in the health care sector this year.
In this segment, Motley Fool health care analysts Brenton Flynn and Max Macaluso take a look at No. 18 on the nice list, Infinity Pharmaceuticals , and how this company left investors with more than a little something extra in their stockings this year.
One massive therapeutic area that Infinity is targeting is arthritis, where Abbott Labs' Humira is taking the world by storm. However, the company is losing this drug next year when it spins off its branded pharma business. It's a confusing event to understand, with many investors left wondering what to do. To help investors better understand the upcoming event, the Fool has created a brand new premium report outlining both Abbott Labs and its spinoff, AbbVie. Inside, we outline all of the must-know opportunities and risks facing both companies, so make sure to claim this 2-for-1 report by clicking here now.
The article The Best of 2012: Infinity Pharmaceuticals originally appeared on Fool.com.Brenton Flynn and Max Macaluso have no positions in the stocks mentioned above. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services recommend Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.